Literature DB >> 27596062

Conformational modulation of the farnesoid X receptor by prenylflavonoids: Insights from hydrogen deuterium exchange mass spectrometry (HDX-MS), fluorescence titration and molecular docking studies.

Liping Yang1, David Broderick1, Yan Campbell2, Adrian F Gombart2, Jan F Stevens3, Yuan Jiang4, Victor L Hsu5, William H Bisson6, Claudia S Maier7.   

Abstract

We report on the molecular interactions of the farnesoid X receptor (FXR) with prenylflavonoids, an emerging class of FXR modulators. FXR is an attractive therapeutic target for mitigating metabolic syndromes (MetS) because FXR activates the inhibitory nuclear receptor, small heterodimer partner (SHP), thereby inhibiting both gluconeogenesis and de novo lipogenesis. We and others have shown that xanthohumol (XN), the principal prenylflavonoid of the hop plant (Humulus lupulus L.), is a FXR agonist based on its ability to affect lipid and glucose metabolism in vivo and to induces FXR target genes in biliary carcinoma cells and HEK293 cells. However, studies are currently lacking to rationalize the molecular mechanisms of FXR modulation by prenylflavonoids. We addressed this deficiency and report the first systematic study of FXR prenylflavonoid interactions. We combined hydrogen deuterium exchange mass spectrometry (HDX-MS) with computational studies for dissecting molecular recognition and conformational impact of prenylflavonoid interactions on the ligand binding domain (LBD) of human FXR. Four prenylflavonoids were tested: xanthohumol, a prenylated chalcone, two prenylated flavonones, namely isoxanthohumol (IX) and 8-prenylnaringenin (8PN), and a semisynthetic prenylflavonoid derivative, tetrahydroxanthohumol (TX). Enhancement of the HDX protection profile data by in silico predicted models of FXR prenylflavonoid complexes resulted in mapping of the prenylflavonoid interactions within the canonical ligand binding pocket. Our findings provide a foundation for the exploration of the chemical scaffolds of prenylated chalcones and flavanones as leads for future structure activity studies of this important nuclear receptor with potential relevance for ameliorating lipid metabolic disorders associated with obesity and MetS.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Farnesoid X receptor; Fluorescence spectroscopy; Hydrogen deuterium exchange; Mass spectrometry; Prenylflavonoids; Xanthohumol

Mesh:

Substances:

Year:  2016        PMID: 27596062      PMCID: PMC5071164          DOI: 10.1016/j.bbapap.2016.08.019

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  61 in total

1.  A spectroscopic investigations of anticancer drugs binding to bovine serum albumin.

Authors:  S Bakkialakshmi; D Chandrakala
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2011-11-18       Impact factor: 4.098

2.  Sterols from a soft coral, Dendronephthya gigantea as farnesoid X-activated receptor antagonists.

Authors:  Kyoungjin Shin; Jungwook Chin; Dongyup Hahn; Jaehwan Lee; Hoosang Hwang; Dong Hwan Won; Jungyeob Ham; Hyukjae Choi; Eunsoo Kang; Hiyoung Kim; Moon Kyeong Ju; Sang-Jip Nam; Heonjoong Kang
Journal:  Steroids       Date:  2012-01-12       Impact factor: 2.668

Review 3.  Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators.

Authors:  Daniel Merk; Dieter Steinhilber; Manfred Schubert-Zsilavecz
Journal:  Future Med Chem       Date:  2012-05       Impact factor: 3.808

4.  A study of the interaction between malachite green and lysozyme by steady-state fluorescence.

Authors:  Fei Ding; Wei Liu; Feng Liu; Zhi-Yuan Li; Ying Sun
Journal:  J Fluoresc       Date:  2009-03-31       Impact factor: 2.217

5.  Quenching of fluorescence by oxygen. A probe for structural fluctuations in macromolecules.

Authors:  J R Lakowicz; G Weber
Journal:  Biochemistry       Date:  1973-10-09       Impact factor: 3.162

6.  Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor.

Authors:  Valentina Sepe; Giuseppe Bifulco; Barbara Renga; Claudio D'Amore; Stefano Fiorucci; Angela Zampella
Journal:  J Med Chem       Date:  2011-02-10       Impact factor: 7.446

7.  A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor.

Authors:  Guodong Li; Wenwei Lin; Juan J Araya; Taosheng Chen; Barbara N Timmermann; Grace L Guo
Journal:  Toxicol Appl Pharmacol       Date:  2011-12-04       Impact factor: 4.219

8.  Methyl parathion interaction with human and bovine serum albumin.

Authors:  Dílson Silva; Célia M Cortez; Jayme Cunha-Bastos; Sônia R W Louro
Journal:  Toxicol Lett       Date:  2004-02-28       Impact factor: 4.372

9.  Hydrogen/deuterium exchange mass spectrometry.

Authors:  Xuguang Yan; Claudia S Maier
Journal:  Methods Mol Biol       Date:  2009

10.  Partial agonists activate PPARgamma using a helix 12 independent mechanism.

Authors:  John B Bruning; Michael J Chalmers; Swati Prasad; Scott A Busby; Theodore M Kamenecka; Yuanjun He; Kendall W Nettles; Patrick R Griffin
Journal:  Structure       Date:  2007-10       Impact factor: 5.006

View more
  8 in total

Review 1.  A current structural perspective on PXR and CAR in drug metabolism.

Authors:  Cameron D Buchman; Sergio C Chai; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2018-05-30       Impact factor: 4.481

2.  Improvements in Metabolic Syndrome by Xanthohumol Derivatives Are Linked to Altered Gut Microbiota and Bile Acid Metabolism.

Authors:  Yang Zhang; Gerd Bobe; Johana S Revel; Richard R Rodrigues; Thomas J Sharpton; Mary L Fantacone; Kareem Raslan; Cristobal L Miranda; Malcolm B Lowry; Paul R Blakemore; Andrey Morgun; Natalia Shulzhenko; Claudia S Maier; Jan F Stevens; Adrian F Gombart
Journal:  Mol Nutr Food Res       Date:  2019-12-15       Impact factor: 5.914

Review 3.  Flavonoids: structure-function and mechanisms of action and opportunities for drug development.

Authors:  Stephen Safe; Arul Jayaraman; Robert S Chapkin; Marcell Howard; Kumaravel Mohankumar; Rupesh Shrestha
Journal:  Toxicol Res       Date:  2021-01-20

4.  Xanthohumol ameliorates Diet-Induced Liver Dysfunction via Farnesoid X Receptor-Dependent and Independent Signaling.

Authors:  Ines L Paraiso; Thai Q Tran; Armando Alcazar Magana; Payel Kundu; Jaewoo Choi; Claudia S Maier; Gerd Bobe; Jacob Raber; Chrissa Kioussi; Jan F Stevens
Journal:  Front Pharmacol       Date:  2021-04-20       Impact factor: 5.988

5.  Targeting the Liver-Brain Axis with Hop-Derived Flavonoids Improves Lipid Metabolism and Cognitive Performance in Mice.

Authors:  Ines L Paraiso; Johana S Revel; Jaewoo Choi; Cristobal L Miranda; Parnian Lak; Chrissa Kioussi; Gerd Bobe; Adrian F Gombart; Jacob Raber; Claudia S Maier; Jan F Stevens
Journal:  Mol Nutr Food Res       Date:  2020-07-06       Impact factor: 5.914

6.  Non-estrogenic Xanthohumol Derivatives Mitigate Insulin Resistance and Cognitive Impairment in High-Fat Diet-induced Obese Mice.

Authors:  Cristobal L Miranda; Lance A Johnson; Oriane de Montgolfier; Valerie D Elias; Lea S Ullrich; Joshua J Hay; Ines L Paraiso; Jaewoo Choi; Ralph L Reed; Johana S Revel; Chrissa Kioussi; Gerd Bobe; Urszula T Iwaniec; Russell T Turner; Benita S Katzenellenbogen; John A Katzenellenbogen; Paul R Blakemore; Adrian F Gombart; Claudia S Maier; Jacob Raber; Jan F Stevens
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

Review 7.  The Potent Phytoestrogen 8-Prenylnaringenin: A Friend or a Foe?

Authors:  Raimo Pohjanvirta; Atefeh Nasri
Journal:  Int J Mol Sci       Date:  2022-03-15       Impact factor: 5.923

8.  Xanthohumol microbiome and signature in healthy adults (the XMaS trial): a phase I triple-masked, placebo-controlled clinical trial.

Authors:  Ryan Bradley; Blake O Langley; Jennifer J Ryan; John Phipps; Douglas A Hanes; Emily Stack; Janet K Jansson; Thomas O Metz; Jan Frederik Stevens
Journal:  Trials       Date:  2020-10-07       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.